Introduction
A common clinical feature of the acquired immunodeficiency syndrome (AIDS) is the reactivation of latent herpesvirus infections such as cytomegalovirus (CMV), varicella-zoster virus (yZV) and herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2).Such reactivations often lead to serious disease owing to the underlying immunodeficiency. Reactivated CMV retinitis can lead to blindness in a matter of weeks if untreated, whilst CMV pneumonia is a cause of death for many AIDS patients. Disseminated VZV or HSV infections are serious and sometimes fatal complications. In addition, there is evidence that the replication of HIV may be potentiated by herpesviruses such as CMVand HHV-6 (Davis et al., 1987; Lusso et aI., 1989) , though this has been disputed (Carrigan et al., 1990; Levy et aI., 1990) . The most commonly used antiherpetic drug, acyclovir (ACV), whilst a good inhibitor of HSV-1 or -2 replication, is less effective against the other herpesviruses, especially CMV, which lacks the viral thymidine kinase (TK) necessary for phosphorylation of the drug (Crumpacker et aI., 197.9 ). There is a need for effective, non-toxic therapies for herpesvirus infections in AIDS patients.
9-(1,3-Dihydroxy-2-propoxymethyl)guanine (DHPG; ganciclovir) is a nucleoside analogue which shows antiviral activity against CMV (Mar et et., 1983; Freitas et al., 1985; Burns and Sandford, 1990; Shigeta et al., 1991) . Clinical use of DHPG against CMV infections has given some encouraging results, especially in the treatment of CMV retinitis (Collaborative DHPG treatment study group, 1986; Crumpacker and Heath-Chiozzi, 1991) . Another promising drug is the acyclic guanosine analogue (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl)guanine ([-]-2HM-HBG), which has potent activity against VZV in vitro and in vivo (Abele et al., 1987; Lake-Bakaar et aI., 1988) . (-)-2HM-HBG was also recently shown by us to have activity against HHV-6 (Akesson Johansson et al., 1990) .
One complication in the treatment of herpesvirus infections in AIDS patients is that antiretroviral therapy is often required at the same time. The interaction between two drugs given simultaneously may lead to unexpected effects, such as synergism or antagonism of the activities of the individual drugs. Therefore, the effect of combining 
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AZT + DHPG AZT Table 1 . Antiherpesvirus spectrum of activity of (-)-2HM-HBG and DHPG. Antiviral activity of the drugs was tested in cell culture in HL cells rJZV, HSV-1 and -2, CMV) or HSB-2 cells (HHV-6). Inhibition of viral replication was measured by virus specific ELISA of cell extracts rJZV, HSV-l and -2, CMV) or immunofluorescence of infected cells together anti herpes and antiretroviral drugs is of importance. 3'-Azido-3'-deoxythymidine (AZT) is currently the anti-HIV drug most commonly used in the treatment of AIDS. Combination of AZT with other antiviral drugs has produced both synergism, When combined with PFA (Koshida et al., 1989b) , dideoxyinosine (Dornsife et aI., 1991) and 3'-fluoro-3'-deoxythymidine (FLT: Koshida et aI., 1989) , and antagonism, when combined with ribavirin (Baba et aI., 1987) . The aim of this study was to investigate the effect upon the antiretroviral activity of AZT and FLT of combination with the promising antiherpes drugs DHPG and (-)-2HM-HBG.
Effect of DHPG on the anti-HIV activity of AZT and FLT
Figures 1 and 2 show the effect of DHPG on the anti-HIV activities of AZT and FLT in the ELISA assay. In both ELISA and IF assays, DHPG reduced the antiviral effect of AZT and FLT. Table 3 shows the IC 5 0's against HIV of AZT and FLT alone and when combined with DHPG. Combination with DHPG raised the IC so of AZTthree-to eightfold, whilst that of FLT was raised three-to fivefold. Table 4 shows the ICso's against HIVof AZT and FLT alone and when combined with (-)-2HM-HBG. The ICso'sof both AZT and FLT were raised three-to fourfold upon combination with (-)-2HM-HBG. The ratio of antiherpes to anti-H IV drug was varied in order to examine whether the antagonism persisted at lower ratios than in the above experiments. The inhibition of viral replication by a fixed concentration of AZT (0.05 fLM) alone orcombined with (-)-2HM-HBG or DHPG at different ratios Table 1 shows the spectrum of activity of (-)-2HM-HBG and DHPG against five different human herpesviruses. We previously showed (-)-2HM-HBG to be more potent against VZV and HHV-6 than DHPG. In contrast, (-)-2HM-HBG was less potent against CMV than DHPG.
Effect of (-)-2HM-HBG on the anti-HIVactivity ofAZT andFLT

Dependence on the ratio of (-)-2HM-HBG or DHPG to AZT
Antiviral spectrum of activity of (-)-2HM-HBG and DHPG
Anti-HIVactivity
The anti-HIV activity of the separate drugs in the ELISA and IF assays is shown in Table 2 . Similar results were given by the two assays. Neither (-)-2HM-HBG nor DHPG showed any anti-HIV activity up to a concentration of 50fLM. Both FLT and AZT showed good anti-HIV activity, with FLT being approximately three-fold more active than AZT. 
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Intracellular metabolism of FLT
The intracellular metabolism of 3H-FLT in H9 cells in the presence of {-)-2HM-HBG or DHPG was analysed by ion exchange HPLC and the intracellular concentrations of FLT metabolites are shown in Table 5 . Neither the total intracellular content of 3H-FLT, nor the levels of the nucleoside, monophosphate or triphosphate were reduced upon incubation with DHPG or {-)-2HM-HBG.
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0.00 is shown in Fig. 3 . Ratios of 10:1 antiherpes:anti-HIV drug and above produced an increasing reversal in the antiviral effect, whilst at a ratio of 1:1 little effect could be seen.
Cytotoxicity
The cytotoxicity of the compounds, alone and in the combinations tested for antiviral activity, was assessed by measuring cell growth at the end of the experiments compared to cells grown without drugs. Neither the drugs alone, nor the various combinations tested, had any effect on the growth of H9 cells at the concentrations and ratios used in these experiments (not shown). , 1990) , which is thought to be closely related to CMV (Lawrence et al., 1990) . Therefore we tested {-)-2HM-HBG for inhibition of CMV replication in comparison to DHPG. However, its activity against CMV was poor in comparison to DHPG, which may indicate its inability to be phosphorylated in CMV-infected cells, or the insensitivity of the CMV DNA polymerase to the triphosphate. Both DHPG and {-)-2HM-HBG showed no activity against the replication of HIV in cell culture. This may be expected, since HIV is not known to induce a viral kinase capable of phosphorylating these drugs, and since their phosphorylation by cellular enzymes in cells in the absence of infection with a herpesvirus is low (Abele et aI., 1987; Crumpacker and Heath-Chiozzi, 1991) . In contrast, AZT and FLT have proven activity against HIV, and are known to be well phosphorylated by the cellular cytosolic thymidine kinase (Furman et al., 1986; Matthes et aI., 1988; Cox and Harmenberg, 1990a) . In spite of their lack of activity individually, both {-)-2HM-HBG and DHPG were able to antagonize the anti-HIV effect of AZT and FLT.This effect was seen at ratios of antiherpes to anti-HIV drug of FLT. The antagonism could be explained by an effect of (-)-2HM-HBG and DHPG upon the intracellular levels of natural deoxynucleoside triphosphates, such as an increase in the level of TIP, which would compete with AZT-and FLT triphosphates for binding to the reverse transcriptase. Further studies are needed to establish the mechanism by which (-)-2HM-HBG and DHPG antagonize the anti-HIV activity of AZT and FLT.
These results are of importance for the treatment of herpes infections in AIDS patients. Although caution must be used in extrapolating from in vitro studies to the clinical situation, these studies indicate that the use of DHPG to treat herpes infection in patients treated with AZT may be less beneficial than expected. Combination of DHPG with AZT in AIDS patients has also been reported to result in severe toxicity (Hochster et al., 1990; Causey, 1991) . The toxicity and potential for antagonism at certain ratios of the combination of AZT with DHPG would appear to limit the usefulness of this particular combination. The antagonistic effects of these combinations should be avoided by not exceeding a 1:1 ratio of antiherpes:anti-HIV drug.
The choice of antiherpes drug for treatment of herpes infections in AIDS patients and ratio of anti-HSV to anti-HIV drug must be made wth care. We have shown that combination of AZT or FLT with phosphonoformate (PFA) produces a synergistic effect against HIV in vitro and a lower cytotoxicity than expected (Koshida et al., 1989a (Koshida et al., , 1989b . PFA, a pyrophosphate analogue, also has a broad range of activity against herpesviruses (Oberg, 1989) . Thus, the use of PFA for the treatment of, for example, CMV infection in AIDS patients being treated with AZT or FLT would seem to have advantages over the use of DHPG.
Note added in proof
During the preparation of this manuscript, the results of a Table 5 . The mechanism of the antagonistic interaction between (-)-2HM-HBG or DHPG and AZT or FLT is not clear. Since both AZT and FLT must be phosporylated by the thymidine salvage pathway to the triphosphate to exert their anti-HIV effect (Furman et aI., 1986; Matthes et al., 1988; Cox and Harmenberg, 1990a) , a reduction in the rate of phosphorylation owing to competition from (-)-2HM-HBG and DHPG might explain the antagonistic effects. However, no effect upon the intracellular metabolism or levels of nucleoside, monophosphate or triphosphate of FLT could be seen when H9 cells were incubated with FLT in the presence of DHPG or (-)-2HM-HBG at a concentration and ratio shown in the antiviral experiments to antagonize the anti-HIV activity of AZT and FLT. This s~ggests that the antagonism seen is not a result of interference in the uptake or phosphorylation of AZT or trial comparing DHPG and PFA for the treatment of CMV retinitis in AIDS patients treated with AZT showed PFA to be superior to DHPG and associated with a longer survival (Studies of ocular complications of AIDS research group, 1992). The synergistic effect of the combination of PFA and AZT compared to the antagonistic effect shown here for DHPG and AZT may explain these recent findings.
Materials and Experimental procedures
Compounds
AZTwas obtained from Sigma Chemical Co., St. Louis, MO, USA. FLT and (-)-2HM-HBG were kind gifts from Professor Bo Oberg, Medivir, Huddinge, Sweden. DHPG was a gift from Merck, Sharp and Dohme, West Point, NY, USA. All compounds were dissolved in cell culture medium for use in the antiviral assay. 3H-FLTwas labelled by Amersham International (Amersham, UK), and was purified before use by reverse phase HPLC (Cox and Harmenberg, 1990a; Cox and Harmenberg, 1990b ).
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Cell culture
For anti-HIV assays, H9 cells (a CD4+ human lymphocyte cell line) were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum and antibiotics in a humidified atmosphere of 7% CO2 in air. For anti-CMV assays, human lung (HL) fibroblasts were grown in Eagle's MEM with 5% fetal calf serum and antibiotics and used when just confluent. Cell number and viability were determined by the trypan blue exclusion method. HIV-1 (HTLV-lIIs ) was obtained from the supernatant of persistently infected H9 cells and stored at -70 DC prior to use. CMV strain AD169 was propagated in HL cells. Cells (2 x 10 s well-1 ) were placed in 24-well microtitre plates and mixed with 0.5 ml of the diluted virus stock. Various concentrations of antiviral.compound(s) were then added in duplicate (after 60 min pre-incubation with virus and removal of the inoculum in the case of CMV). After 7 days incubation at 37"C, the cytotoxicity of the drugs and combinations was measured, and viral growth was measured for HIV by HIV-1-specific ELISAof the supernatants and by immunofluorescence of the infected cells, and for CMV by CMV-specific ELISA of cell extracts.
HIV ELISA Antigen content of the culture supernatants was measured by HIV-1-specific ELISA (Sundqvist et al., 1989) . Briefly, culture supernatants were diluted and incubated overnight at room temperature in microtitre plates coated with human anti-HIV-1 IgG (National Bacteriological Laboratory, Stockholm, Sweden). The plates were washed, and a horseradish peroxidase (HRPO)-conjugated mouse monoclonal antibody directed against the HIV-1 p24 protein (National Bacteriological Laboratory) was added. The plates were incubated for 2h at 37"C, washed, and substrate (ortho-phenylenediamine dihydrochloride, OPD; Sigma Chemical Co., St. Louis, MO, USA)added. After 30 min incubation at room temperature, the reaction was stopped by addition of
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2.5 M H2S04, and the absorbance at 490 nm read. The assay was calibrated by the inclusion of an HIV-1 antigen standard curve on each plate.
Immunofluorescence (IF)
The antigen content of infected cells was measured by immunofluorescence (Bazin et al., 1989) . Briefly, cells were spotted onto 8-well microscope slides and allowed to air dry. After fixing in cold methanol , human anti-HIV-1 antiserum containing IgG to all major HIV proteins (National Bacteriological Laboratory, Stockholm, Sweden) was added and the slides incubated in a humid chamber for 30 min at 37"C. The slides were washed, and a fluorescein isothiocyanate (FITC)-Iabelledsheep anti-human IgG (National Bacteriological Laboratory, Stockholm, Sweden) was added and the slides incubated for a further 30 min. After washing and counterstaining with Evan's blue, the slides were examined in a fluorescence microscope, and the percentage of infected cells calculated.
CMVELISA
Antigen content of cells was measured by CMV-specific ELISA (Wahren et al., 1983) . Briefly, cells were broken by addition of 0.8ml water per well, freeze thawing and sonication. Extracts were made isotonic by the addition of 0.2 mI4.5% NaC!. The ELISA was performed as for the HIV ELISA, using a sandwich technique with primary and secondary rabbit anti-CMV IgGs (National Bacteriological Laboratory, Stockholm, Sweden) and an alkaline phosphatase-conjugated anti-rabbit IgG (Orion Diagnostica, Helsinki, Finland). The substrate was p-nitrophenyl phosphate (Sigma Chemical Co., St. Louis, MO, USA), and the absorbance read at 410nm. A CMVantigen standard was included on each plate.
Cytotoxicity
The toxicity of the separate drugs and combinations was assessed by measuring the growth of the cells in a volume distribution analyser after 7 days in comparison to control wells incubated without drugs.
Drug interaction calculations
The activity of the drugs was measured for each drug alone, and mixed together in a fixed ratio determined by theirrelative ICso's, according to the established median effect method for analysis of drug combinations (Chou and Talalay, 1983) . In this case, since DHPG and (-)-2HM-HBG were shown to be without anti-HIV activity, they were mixed with the anti-HIV drugs at a ratio to reflect approximately their anti-herpes activity relative to the anti-HIV activity of AZT and FLT (I.e. 100:1).
Calculation of results
The inhibition of viral replication in ELISA or IF assays was calculated by comparison to infected cells incubated without drug. Each assay was performed in duplicate, and the mean result used to calculate the IC so graphically using regression analysis. The correlation coefficient (r)for every experiment was >0.95 and usually~0.98. Each experiment was performed at least twice, and the IC so calculated as the mean of the separate experiments.
Intracellular metabolism of FLT
The effect of DHPG and (-)-2HM-HBG on the intracellular metabolism of FLT in H9 lymphocytes was analysed by high performance liquid chromatography (HPLC). H9 cells were incubated with 0.01/-LM 3H-FLT in the absence and presence of 5/-LM DHPG or (-)-2HM-HBG. After incubation for 20h at 3rC, the cells were harvested by centrifugation, completely drained of medium and extracted in the presence of 6% cold trichloroacetic acid. Extracts were neutralized by the amine-freon method (Chen et a/., 1977) . This method of preparing cell extracts has been previously shown to give excellent recovery of nucleotides (Harmenberg et al., , 1990 . The total intracellular concentration of H-FLT in the extracts was measured by scintillation counting. The intracellular metabolism of 3H-FLTwas analysed by ion exchange 3HPLC on a Waters chromatograph equipped with a dual wavelength absorbance detector (254 and 280nm). The analyses were performed on a Whatman Partisil 10 SAX column, 0.4 x 25cm Harmenberg, 1990a, 1990b) . The mobile phase was 50mM phosphate buffer, pH 3.5, at 1ml rnin" for analysis of nucleoside and monophosphate, rising to 0.5 M for analysis of triphosphate content. 0.5 min fractions were collected and the radioactivity content measured by scintillation counting. The analysis of intracellular FLT metabolites using HPLC and retention times have previously been described Harmenberg, 1990a, 1990b) .
